2021
Preliminary Safety and Efficacy Results from Precizn-1: An Ongoing Phase 1/2 Study on Zinc Finger Nuclease-Modified Autologous CD34+ HSPCs for Sickle Cell Disease (SCD)
Alavi A, Krishnamurti L, Abedi M, Galeon I, Reiner D, Smith S, Wang L, Ramezi A, Rendo P, Walters M. Preliminary Safety and Efficacy Results from Precizn-1: An Ongoing Phase 1/2 Study on Zinc Finger Nuclease-Modified Autologous CD34+ HSPCs for Sickle Cell Disease (SCD). Blood 2021, 138: 2930. DOI: 10.1182/blood-2021-151650.Peer-Reviewed Original ResearchSickle cell diseaseVaso-occlusive crisisAdverse eventsAutologous CD34Apheresis cyclesWeek 26Cell diseaseSpeakers bureauTotal HbOngoing phase 1/2 studySevere sickle cell diseaseF cellsPhase 1/2 studyBaseline patient characteristicsRelated adverse eventsHealth-related qualityPeripheral blood WBCCurrent unmet needPotential therapeutic valueEarly termination visitMinimum cell doseStem cell engraftmentTrend of improvementCurrent employmentElevated fetal hemoglobinEffects of MTX-23, a Novel PROTAC of Androgen Receptor Splice Variant-7 and Androgen Receptor, on CRPC Resistant to Second-Line Antiandrogen Therapy
Lee G, Nagaya N, Desantis J, Madura K, Sabaawy H, Kim W, Vaz R, Cruciani G, Kim I. Effects of MTX-23, a Novel PROTAC of Androgen Receptor Splice Variant-7 and Androgen Receptor, on CRPC Resistant to Second-Line Antiandrogen Therapy. Molecular Cancer Therapeutics 2021, 20: 490-499. PMID: 33277442, DOI: 10.1158/1535-7163.mct-20-0417.Peer-Reviewed Original ResearchConceptsCastration-resistant prostate cancerSecond-line antiandrogen therapyAR full lengthAndrogen receptor splice variant 7AR-V7Antiandrogen therapyAndrogen-responsive prostate cancer cellsProstate cancer cellular proliferationHuman prostate cancer cell linesProstate cancer cell linesStandard of careCancer cellular proliferationCellular proliferationPotential therapeutic valueProstate cancer cellsAgents abirateroneCancer cell linesProteolysis Targeting ChimerasMechanisms of resistanceAndrogen receptorAR DNAProstate cancerTumor growthTherapeutic valueAntiproliferative effects
2015
Auditory Pathology in a Transgenic mtTFB1 Mouse Model of Mitochondrial Deafness
McKay SE, Yan W, Nouws J, Thormann MJ, Raimundo N, Khan A, Santos-Sacchi J, Song L, Shadel GS. Auditory Pathology in a Transgenic mtTFB1 Mouse Model of Mitochondrial Deafness. American Journal Of Pathology 2015, 185: 3132-3140. PMID: 26552864, PMCID: PMC5801480, DOI: 10.1016/j.ajpath.2015.08.014.Peer-Reviewed Original ResearchMeSH KeywordsAMP-Activated Protein KinasesAnimalsApoptosisDeafnessDisease Models, AnimalDNA, MitochondrialEvoked Potentials, Auditory, Brain StemHair Cells, Auditory, InnerMice, Inbred C57BLMice, KnockoutMice, TransgenicMitochondrial DiseasesMutationOrgan of CortiReaction TimeSignal TransductionSpiral GanglionStria VascularisTranscription FactorsConceptsAMP kinaseReactive oxygen species-mediated activationTranscription factor E2F1A1555G mutationAuditory pathologyHair cellsTFB1MHearing loss phenotypeRRNA geneAMPK-α1AMPK activityProlonged wave I latencyLoss phenotypeMitochondrial pathologyNonsyndromic deafnessTransgenic mouse strainWave I latencySpiral ganglion neuronsProgressive hearing lossMitochondrial deafnessPotential therapeutic valueDNA causeG mutationOuter hair cellsI latency
2014
Restoration of Impaired Endothelial Myocyte Enhancer Factor 2 Function Rescues Pulmonary Arterial Hypertension
Kim J, Hwangbo C, Hu X, Kang Y, Papangeli I, Mehrotra D, Park H, Ju H, McLean DL, Comhair SA, Erzurum SC, Chun HJ. Restoration of Impaired Endothelial Myocyte Enhancer Factor 2 Function Rescues Pulmonary Arterial Hypertension. Circulation 2014, 131: 190-199. PMID: 25336633, PMCID: PMC4293354, DOI: 10.1161/circulationaha.114.013339.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsApelinArteriolesCells, CulturedDisease Models, AnimalDrug Evaluation, PreclinicalEndothelial CellsFibroblast Growth Factor 2HemodynamicsHistone Deacetylase InhibitorsHydroxamic AcidsHypertension, PulmonaryHypertrophy, Right VentricularHypoxiaIntercellular Signaling Peptides and ProteinsMaleMEF2 Transcription FactorsMicroRNAsMonocrotalinePulmonary ArteryPyrrolesRatsRats, Sprague-DawleyRNA InterferenceRNA, Small InterferingTranscription, GeneticConceptsPulmonary arterial hypertensionPulmonary artery endothelial cellsPulmonary vascular homeostasisPAH-pulmonary artery endothelial cellsMyocyte enhancer factor 2Arterial hypertensionCauses of PAHVascular homeostasisExperimental pulmonary hypertension modelsIncreased pulmonary arterial pressurePulmonary artery smooth muscle cellsArtery smooth muscle cellsMEF2 activityRight ventricular failurePulmonary arterial pressurePulmonary hypertension modelPotential therapeutic strategyPotential therapeutic valueSmooth muscle cellsArtery endothelial cellsFactor 2Potential adverse effectsTranscription factor myocyte enhancer factor 2Class IIa HDACsVentricular failureThe angiotensin type 2 receptor agonist Compound 21 elicits cerebroprotection in endothelin-1 induced ischemic stroke
Joseph JP, Mecca AP, Regenhardt RW, Bennion DM, Rodríguez V, Desland F, Patel NA, Pioquinto DJ, Unger T, Katovich MJ, Steckelings UM, Sumners C. The angiotensin type 2 receptor agonist Compound 21 elicits cerebroprotection in endothelin-1 induced ischemic stroke. Neuropharmacology 2014, 81: 134-141. PMID: 24508710, PMCID: PMC7472595, DOI: 10.1016/j.neuropharm.2014.01.044.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin II Type 2 Receptor BlockersAnimalsBrain InfarctionBrain IschemiaCD11b AntigenCerebrovascular CirculationCytokinesDisease Models, AnimalDose-Response Relationship, DrugEndothelin-1Glial Fibrillary Acidic ProteinImidazolesMaleNitric Oxide Synthase Type IIPeroxidasePyridinesRatsRats, Sprague-DawleyStrokeSulfonamidesThiophenesTime FactorsConceptsMiddle cerebral artery occlusionPost-stroke administrationEndothelin-1Neurological deficitsIschemic strokeCerebroprotective actionCerebral damageCerebral ischemiaAT2R agonistChemokine (C-C) motif ligand 2Inducible nitric oxide synthaseBeneficial effectsCerebral infarct sizeMCAO-induced increaseCerebral artery occlusionAnti-inflammatory effectsCerebral blood flowNitric oxide synthaseSelective AT2R agonistPotential therapeutic valueType 2 mRNAAT2R inhibitorArtery occlusionPeripheral administrationHemorrhagic stroke
2013
Renalase in hypertension and kidney disease
Desir GV, Peixoto AJ. Renalase in hypertension and kidney disease. Nephrology Dialysis Transplantation 2013, 29: 22-28. PMID: 24137013, DOI: 10.1093/ndt/gft083.Peer-Reviewed Original Research
2001
Stimulating Effects of Low-Dose Fructose on Insulin-Stimulated Hepatic Glycogen Synthesis in Humans
Petersen K, Laurent D, Yu C, Cline G, Shulman G. Stimulating Effects of Low-Dose Fructose on Insulin-Stimulated Hepatic Glycogen Synthesis in Humans. Diabetes 2001, 50: 1263-1268. PMID: 11375325, DOI: 10.2337/diabetes.50.6.1263.Peer-Reviewed Original ResearchConceptsNet hepatic glycogen synthesisHepatic glycogen synthesisGlycogen synthesisSynthase fluxInfusion of fructoseLow-dose infusionType 2 diabetesEuglycemic hyperinsulinemic conditionsPotential therapeutic valueHepatic glycogen metabolismThreefold increaseFructose studiesEuglycemic hyperinsulinemiaHyperinsulinemic conditionsFructose infusionControl studyTherapeutic valueInfusionType 1Glucokinase activityGlycogen metabolismIndirect pathwaysStimulating effectInsulinStimulation
1994
EFFECTS OF LIGHT ON T‐CELLS IN HIV‐INFECTED SUBJECTS ARE NOT DEPENDENT ON HISTORY OF SEASONAL AFFECTIVE DISORDER
Rosenthal N, Brown C, Oren D, Galetto G, Schwartz P, Malley J. EFFECTS OF LIGHT ON T‐CELLS IN HIV‐INFECTED SUBJECTS ARE NOT DEPENDENT ON HISTORY OF SEASONAL AFFECTIVE DISORDER. Photochemistry And Photobiology 1994, 59: 314-319. PMID: 7912442, DOI: 10.1111/j.1751-1097.1994.tb05040.x.Peer-Reviewed Original ResearchConceptsSeasonal affective disorderSuppressor T-cell countsSignificant mood improvementPotential therapeutic valuePlasma cortisol levelsCD8 levelsHigher CD4Treatment modalitiesT cellsLight therapyCortisol levelsCrossover designAffective disordersCell countHIVTherapeutic valueMood improvementBright light conditionsSignificant differencesTreatment conditionsHigher cell countsDisordersSubjectsVisible red lightCount
1987
Central dopamine-peptide interactions: Electrophysiological studies
Bunney B. Central dopamine-peptide interactions: Electrophysiological studies. Neuropharmacology 1987, 26: 1003-1009. PMID: 3309707, DOI: 10.1016/0028-3908(87)90079-7.Peer-Reviewed Original ResearchConceptsDA systemSelective non-peptide antagonistMidbrain DA systemsCentral DA systemsNon-peptide antagonistsPotential therapeutic valuePotential clinical interestDA neuronsDA cellsElectrophysiological studiesMental disordersTherapeutic valueEffects of peptidesSpecific receptorsAnatomical evidenceClinical interestEndogenous substancesPeptide systemBrainPhysiological activityVariety of peptidesBehavioral studiesPhysiological relevancePeptidesActive peptides
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply